News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opexa Pharmaceuticals, Inc. Regains NASDAQ Compliance Following Stem Cell Agreement


8/10/2009 9:43:02 AM

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today announced that on August 7, 2009, the Company received notice that the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“NASDAQ”) has determined that Opexa has regained compliance with the continued listing requirements and shall remain listed on The NASDAQ Capital Market. This follows last week’s announcement of Opexa’s agreement with Novartis, a leading global pharmaceutical company, whereby Novartis acquired Opexa’s stem cell technology in a deal potentially valued at over $50 million.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES